Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates

Chris Anzalone, President and Chief Executive Officer at Arrowhead

“Together, these data demonstrate the breadth of our cardiometabolic portfolio and our progress toward addressing serious consequences of lipid disorders.”

Chris Anzalone, President and Chief Executive Officer at Arrowhead

“Plozasiran’s reduction in acute pancreatitis event rates in SHASTA-3 and SHASTA-4, alongside sustained triglyceride lowering through up to three years of treatment in PALISADE, reinforces its potential to make a meaningful difference for patients.”

Chris Anzalone, President and Chief Executive Officer at Arrowhead

“With ARO-DIMER-PA, we are extending the capabilities of our TRiM™ (Targeted RNAi Molecule) platform by targeting two genes with a single RNAi molecule, with the goal of addressing both LDL cholesterol and triglyceride-rich lipoproteins in people with mixed hyperlipidemia.”

James Hamilton, Chief Medical Officer and Head of R&D at Arrowhead

“These findings highlight the importance of looking beyond triglyceride levels alone to understand a patient’s risk of acute pancreatitis.”

James Hamilton, Chief Medical Officer and Head of R&D at Arrowhead

“In the SHASTA-3 and SHASTA-4 pooled analysis, plozasiran reduced acute pancreatitis event rates by 78% overall versus placebo and by 91% among patients who had experienced pancreatitis within five years before screening.”

James Hamilton, Chief Medical Officer and Head of R&D at Arrowhead

“The PALISADE long-term extension found sustained triglyceride and APOC3 reductions through up to three years of treatment in patients with FCS.”

James Hamilton, Chief Medical Officer and Head of R&D at Arrowhead

“Meanwhile, the early ARO-DIMER-PA results show the potential to address multiple lipid abnormalities with a single molecule, supporting further evaluation of this approach for patients with mixed hyperlipidemia.”